Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $345 from $360 and keeps an Equal Weight rating on the shares. The firm says ...

First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features state-of-the-art advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with ...